Gardner et al. reported on two unique CD19-negative relapses arising from an ALL to AML lineage switch shortly after CART19 cell therapy in two out of seven treated patients with mixed lineage leukemia (MLL) B-ALL(28). Here, CD19 is linked to acute lymphoblastic leukemia.